MedTrace Logo

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

NCT01068860 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 246

Last updated 2011-09-05

Study results available
· View outcomes & findings →

Summary

This was a 10-week, placebo-controlled, randomized study to investigate the effect of injectable IL-1B antagonist, Canakinumab , in participants with impaired glucose tolerance or Type 2 Diabetes Mellitus (T2DM) already treated on different background diabetes therapies.

Conditions

Interventions

DRUG

Canakinumab 150 mg

Single subcutaneous injection of Canakinumab 150 mg.

DRUG

Placebo to Canakinumab

Single subcutaneous injection of Placebo to Canakinumab.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals Corporation · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • United States
  • Australia
  • Canada
  • Finland
  • Germany
  • India
  • Italy

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01068860 on ClinicalTrials.gov